Skip to main content
IMS Events Main banner
Rate ePoster

    Imaging, QoL and Patient-Reported Outcome and Supportive Care

    Category: Imaging, QoL and Patient-Reported Outcome and Supportive Care

    Health-Related Quality of Life in a "real-world" cohort of Chilean patients with Multiple Myeloma.

    (PA-138) Health-related Quality of Life in a "Real-world" Cohort of Chilean Patients with Multiple Myeloma

    Friday, September 19, 2025

    Introduction:      The advances in new therapeutic options in multiple myeloma (MM) have improved survival rates. However, due to the disease itself or its treatment, patients experience deterioration in other physical, social, and emotional aspects, which is why quality of life Health-related quality of life (HRQoL) is an important variable to understand. There is no data on HRQoL in a Chilean cohort. The main aim was to evaluate HRQoL in a consecutive cohort of patients with multiple myeloma (MM) from 2023 to 2024, at different stages of the disease.

    Methods:   Observational cross-sectional study. The surveyed patients were divided into newly diagnosed patients (NDMM), refractory or relapsed patients (RRMM), and triple-class exposed or triple-class refractory patients (TCE/TCR), defined as patients who had used at least one IMID, one proteasome inhibitor, and one anti-CD38 monoclonal antibody. Additionally, sociodemographic and clinical data were collected. The EORTC QLQ-C30 questionnaire (for cancer in general), and the MY20, (specific for MM), both validated in Chile, were used. Results were analyzed according to the guidelines of the corresponding EORTC manual. The study was approved by the corresponding ethics committee.

    Results:   

    A total of 186 patients were evaluated. 51.2% were male, with an median age of 68 years. The global HRQoL in the cohort was 56.3 (SD 23.2), with 59.0 (SD 24.4) for NDMM, 52.9 (SD 22.7) for RRMM, and 68.9 (SD 14.4) for TCE/TCR (p=0.023), where the latter group was significantly younger, with ages of 67.8 vs 73.3 vs 55.7 years respectively (p< 0.001). In terms of analysis by other subgroups, women had worse perceptions on the physical functioning scale (p=0.014), fatigue (p=0.005), nausea and vomiting (p=0.011), dyspnea (p=0.007), loss of appetite (p=0.008), constipation (p=0.014), adverse effects (p< 0.001), and body image (p=0.002). Patients with PS ≥2 had worse perception on the global HRQoL scale (p=0.001), in physical functioning (p=0.002), role (p=0.016), emotional (p=0.050), and cognitive (p=0.001) scales, as well as on the pain (p=0.020), insomnia (p=0.045), and adverse effects scales (p< 0.001). By age groups (< 60, between 60 and 75, and > 75 years), worse perception of social functioning (p=0.047), insomnia (p=0.014), and financial difficulties (p=0.001) were observed in those under 60 years old. There were no differences in HRQoL by treatment line, BMI, or education level.

    Conclusions:   

    Global HRQoL was low in these patients, similar to other studies. The best perception was reported by TCE/TCR patients, which may be due to them being younger patients. Women, patients with ECOG PS ≥2, and those < 60 years old have significantly worse perception of their HRQoL in several aspects. This study sheds light on which groups should be intervened in certain areas of their HRQoL during the course of their illness.